<Back to Therapeutic Areas

Respiratory

Meet Us

AAFP | Oct 13-17, 2020 │ Virtual

CHEST | Oct 18 -21, 2020 │ Virtual

ACAAI | Nov 13-15, 2020 │ Virtual

ADVAIR DISKUS

250/50 (fluticasone propionate 250 mcg and salmeterol 50 mcg inhalation powder)

Material Safety Data Sheets Environmental Risk Assessments

ADVAIR HFA

45/21, 115/21, 230/21 (fluticasone propionate 45 mcg, 115 mcg, 230 mcg and salmeterol 21 mcg) Inhalation Aerosol

Material Safety Data Sheets Environmental Risk Assessments

BECONASE AQ

(beclomethasone dipropionate, monohydrate) Nasal Spray, 42 mcg

Material Safety Data Sheets Environmental Risk Assessments

BREO ELLIPTA

(fluticasone furoate 100 mcg and vilanterol 25 mcg inhalation powder)

Material Safety Data Sheets Environmental Risk Assessments

FLOVENT DISKUS

50 mcg/100 mcg/250 mcg (fluticasone propionate inhalation powder, 50 mcg/100 mcg/250 mcg)

Material Safety Data Sheets Environmental Risk Assessments

FLOVENT HFA

HFA 44 mcg/110 mcg/220 mcg (fluticasone propionate 44 mcg/110 mcg/220 mcg) Inhalation Aerosol

Material Safety Data Sheets Environmental Risk Assessments

Asthma

The Role of Eosinophils and Their Potential Heterogeneity in Airways Disease (50:00)

Uncontrolled Asthma: Changing the Patient Experience (20:07)

COPD

COPD Introduction With Dr. Corbridge (6:50)

Spirometry With Dr. Corbridge (5:23)


Exacerbations With Dr. Mannino (5:32)

Exacerbation Case Study With Dr. Mannino (2:29)

Dyspnea Overview With Dr. Soler (2:45)

Dyspnea Treatment With Dr. Soler (2:33)

Dyspnea Case Study With Dr. Lettieri (4:40)

Treatable Traits With Dr. Corbridge (13:53)

EGPA

On-Demand Webinars

Presented by: Dr. Michael E. Wechsler, MD, MMSc

EGPA: Pathogenesis, Diagnosis, and Management (28:06)


EGPA Mechanism of Disease (3:54)

American Thoracic Society (ATS)

Aug 5-10, 2020 | Virtual

AAAAI

Mar 13-16, 2020 | Philadelphia, PA (Cancelled due to COVID-19)

  Contact Us